Patents by Inventor Mario Pablo Estrada Garcia

Mario Pablo Estrada Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptidic Growth Hormone Secretagogues Analog Compounds and Preparations Thereof
    Publication number: 20100055118
    Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.
    Type: Application
    Filed: February 28, 2007
    Publication date: March 4, 2010
    Applicant: CENTRO DE INGENÍERA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia Del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
  • NEUROPEPTIDES FOR AQUATIC ORGANISMS CULTURE
    Publication number: 20090176703
    Abstract: The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 9, 2009
    Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Juana Maria Lugo Gonzalez, Mario Pablo Estrada Garcia, Alina Rodriguez Mallon, Yamila Carpio Gonzalez, Antonio Morales Rojas, Osmany Rodrigo Gonzalez De Sosa, Reynold Morales Fernandez, Fidel Francisco Herrera Miyares
  • Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
    Patent number: 7361638
    Abstract: This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: April 22, 2008
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jorge Berlanga Acosta, Gerardo Enrique Guillen Nieto, Diana Garcia Del Barco Herrera, Julio Raul Fernandez Masso, Mario Pablo Estrada Garcia, Isabel Guillen Perez, Jose Suarez Alba, Rebeca Martinez Rodriguez
  • Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
    Publication number: 20030186865
    Abstract: This invention relates to human medicine, and particularly with a pharmaceutical combination made up with Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP); being useful to prevent tissue damages due to blood flow suppression as to enhance tissue repair following ischaemic damages. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or organs are exposed to prolonged ischaemic periods.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 2, 2003
    Inventors: Jorge Berlanga Acosta, Gerardo Enrique Guillen Nieto, Diana Garcia Del Barco, Julio Raul Fernandez Masso, Mario Pablo Estrada Garcia, Isabel Guillen Perez, Jose Suarez Alba, Rebecca Martinez Rodriguez